Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590312 | 1.00 | JAK1 (0.45) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL2800101 | 0.89 | JAK2 (0.56) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL2800837 | 0.84 | JAK2 (0.52) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL2800150 | 0.83 | JAK2 (0.45) | JAK1JAK2TYK2ABL1JAK3 | |
| Tert-Butyl Formate SCHEMBL27776921 | 0.80 | JAK2 (0.49) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL2799229 | 0.79 | PIK3CA (0.49) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL24291840 | 0.78 | EGFR (0.45) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL27866956 | 0.77 | JAK2 (0.41) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL27866955 | 0.77 | EGFR (0.42) | JAK1JAK2TYK2ABL1JAK3 | |
| SCHEMBL27091084 | 0.76 | FGFR3 (0.45) | JAK1JAK2TYK2ABL1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 4/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | JAK1 2486/4885JAK2 2513/4885TYK2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.